CorriXR Therapeutics Founder Eric Kmiec said the startup company is targeting clinical trials within 18 months, bolstered with results of a new study. | PHOTO COURTESY OF CORRIXR
CorriXR study finds promising results in lung cancer treatment
WILMINGTON — CorriXR Therapeuticshas unveiled preliminary data from a study that shows that its gene-editing technology can help treat solid cancer tumors as it eyes manufacturing agreements in the future.
The life science startup, which spun out of the ChristianaCare Gene Editing Institute in 2022, has published preclinical data in “Molecular Therapy Oncology” that shows that its treatment had disabled NRF2 gene in tumors, making them more susceptible to chemotherapy.
The 18-month study was completed in collaboration with ChristianaCare’s Gene Editing Institute led by the study’s lead author and the institute’s Associate Director of Research Kelly Banas.
Eric Kmiec, founder and CEO of CorriXR Therapeutics and executive director at ChristianaCare’s Gene Editing Institute, called the report a “tour-de-force” that put the startup company’s work in the past year to help treat cancer effectively and with little pain for the patients.
“All of our work is based on the concept of reducing suffering in patients. That’s bred into us at ChristianaCare,” Kmiec said. “Just to be able to reduce the amount of pain and suffering for these patients, especially when they have to be on this type of chemotherapy or radiation, is a big goal. We’re pretty excited about that.”
